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A B S T R A C T
Background: Identifying patients with acute heart failure (HF) at high risk for readmission or death after
hospital discharge will enable the optimization of treatment and management. The objective of this
study was to develop a risk score for 30-day HF-specific readmission or death in Korea.
Methods: We analyzed the data from the Korean Acute Heart Failure (KorAHF) registry to develop a risk
score. The model was derived from a multiple logistic regression analysis using a stepwise variable
selection method. We also proposed a point-based risk score to predict the risk of 30-day HF-specific
readmission or death by simply summing the scores assigned to each risk variable. Model performance
was assessed using an area under the receiver operating characteristic curve (AUC), the Hosmer–
Lemeshow goodness-of-fit test, the net reclassification improvement (NRI), and the integrated
discrimination improvement (IDI) index to evaluate discrimination, calibration, and reclassification,
respectively.
Results: Data from 4566 patients aged40 years were included in the analysis. Among them, 446 (9.8%)
had 30-day HF-specific readmission or death. The final model included 12 independent variables (age,
New York Heart Association functional class, clinical history of hypertension, HF admission, chronic
obstructive pulmonary disease, etiology of cardiomyopathy, systolic blood pressure, left ventricular
ejection fraction, serum sodium, brain natriuretic peptide, N-terminal prohormone of brain natriuretic
peptide at discharge, and prescription of b-blockers and angiotensin-converting enzyme inhibitors or
angiotensin II receptor antagonists at discharge). The point risk score showed moderate discrimination
(AUC of 0.710; 95% confidence interval, 0.685–0.735) and good calibration (x2 = 8.540, p = 0.3826).
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Introduction
Heart failure (HF) is a leading cause of mortality and morbidity
and represents a serious public health concern due to the frequency
withwhichit isnecessarytohospitalizetheglobalelderlypopulation
for this condition relative to other cardiovascular diseases [1–4]. In
2016, 5.7 million people over the age of 20 years had HF in the USA,
and its prevalence is predicted to increase by 23%, from 2.42% in
2012 to 2.97% in 2030 [5–7]. The burden of hospitalization due to HF
is expected to become increasingly serious as the global population
ages.Additionally, the readmissionrateofpatientswithHFfollowing
discharge is also high, with over 20% of patients requiring
rehospitalization within 30 days [1,8]. Therefore, identifying
potential approaches to lowering the hospital readmission rate
could be seen as a priority [9]. Many clinical trials and observational
studies have shown that a range of interventions after hospital
discharge, including post-hospital nursing and physician follow up,
can effectively reduce the rate of readmission [10–14].
In the past two decades, several predictive models have been
developed to identify high-risk patients who are considered to
pose a high readmission risk andwhomight benefit from intensive
interventions [15,16]. The readmission rates determined by the
Centers for Medicare and Medicaid Services in the USA were
recently used to assess hospital performance [17]. Despite its
evident potential value, a scoring system that enables the risk of
readmission to be calculated has not been available in Asian
countries. Those that are available have largely been based on
general US or European populations due to the lack of primary
clinical data from Asian populations [15].
Therefore, the objective of this study was to provide a simple
and valid risk score to estimate the 30-dayHF-specific readmission
or death risk after hospital discharge based on the Korean national
HF registry.
Methods
Study population and measurements
The Korean Acute Heart Failure registry (KorAHF), supported by
the Korea National Institute of Health (KNIH), was established in
March 2011. It is an ongoing, prospective, observational study
conducted at 10 tertiary hospitals to collect data on patients with
acute decompensated heart failure. Information on patient char-
acteristics, treatments, and short- and long-term major outcomes
wasobtained,andtheethnicandregionalprofilesof thesamplewere
comparedwith those of other representativeHF registries (ADHERE,
ATTEND, OPTIMIZE-HF, EHFSII, THESUS-HF, and ADHERE Interna-
tional) [18–20]. The protocol of the KorAHF was approved by the
Institutional Review Board of each participating hospital. Written
consent was obtained from each patient; if the patient could not
agree because of disease severity, informed consent was obtained
from a relative or legal representative.
From 2011 to 2014, 5625 consecutive HF patients were enrolled
at admission. All patients were evaluated to determine whether
they met the eligibility criteria, which were based on the
2005 European Society of Cardiology guidelines. Real-time
administrative data were collected using the Internet-based
Clinical Research and Trial management system (iCReaT), sup-
ported by the KNIH. Information on a patient's demographic
characteristics, eligibility evaluation, clinical history, symptoms,
physical measurements, electrocardiographic findings, medica-
tions, additional treatments, complications, and outcomes was
collected at admission and during the follow-up periods. By 2016,
at least 1 year of follow-up data had been collected for all patients,
including information on the cause of death or readmission and
various clinical measurements. The KorAHF study design has been
described in detail previously [21,22].
Statistical methods
The baseline characteristics of patients and their risk of 30-day
HF-specific readmission or death were compared using chi-square
tests and t-tests for categorical and continuous variables, respec-
tively. The clinical histories and etiologies of HF patients were
evaluated dichotomously (yes or no) [21]. The primary exposures of
interest in themodelwere alsodivided into twocategories: smoking
status (current smoker or ex- and never smoker), alcohol consump-
tion (heavy drinker or social/never drinker), New York Heart
Association (NYHA) functional class (I-II or III-IV), concomitant
medication at admission and discharge (used or not used), systolic
blood pressure (SBP <110 or 110 mmHg), serum sodium level (Na
<135 or135 mmol/L), serum creatinine level (Cr>2.0 or2.0 mg/
dl), left ventricular ejection fraction (LVEF <40 or 40%), length of
stay (LOS <7 or 7 days), and body mass index (BMI <18.5 or
18.5 kg/m2). Most hospitals participating in this registry routinely
collected data on either brain natriuretic peptide (BNP) or N-
terminal prohormone of brain natriuretic peptide (NT-proBNP)
levels. Next, we created composite variables by combining two
individual variables, and we defined BNP 700 or NT-proBNP
8000 pg/mL as an elevated natriuretic peptide level. Specifically,
weused thedifference in thesensitivityandspecificity, aswell as the
Youden index, to approximate the optimal cut-off points forNa, BNP,
and NT-proBNP (see Supplementary Appendix, eTable 1).
Multiple logistic regression analysis with a stepwise variable
selectionmethod (using a significant level of entry of 0.2 and a stay
of 0.05) was used to explore risk factors that were associated with
30-day HF-specific readmission and death and to build the risk
prediction model. Using the method described above, we first
constructed (1) a complex model with all significant clinical and
biochemical variables that were screened; we then developed (2) a
basic model with only age and biochemical variables in a complex
model, and (3) a clinical model with traditional clinical risk factors
for HF readmission. All the estimated coefficients of the variables
contained in the complex model were used to assign point values
to the specific categories of each predictor. Finally, the risk score for
30-dayHF-specific readmission or deathwas calculated as the sum
of these points. A simple mathematical equation was used to
correlate this risk score with the actual incidence rate of 30-day
readmission or death. The general method for constructing a point
risk has been well described in a previous study [23].
Toevaluate theeffectof theadditionofbiochemicalmeasurements
on the clinical model's capability, we tested its discrimination and
reclassification abilities by the receiver operating characteristic (ROC)
curve and the area under the curve (AUC), the net reclassification
Conclusions: The risk score for the prediction of the risk of 30-day HF-specific readmission or death after
hospital dischargewas developed using 12 predictors. It can be utilized to guide appropriate interventions
or care strategies for patients with HF.
© 2018 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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improvement (NRI), and the integrated discrimination improvement
(IDI). AUCs were compared using the method suggested by DeLong
et al. [24]. The goodness-of-fit test statistics were also calculated to
assess the calibration for the prediction models using the Hosmer–
Lemeshow method [25]. A two-tailed p-value <0.05 was deemed to
indicatestatistical significance.SASversion9.4(SASInstitute,Cary,NC,
USA) was used for all analyses.
Results
Of the 5625 patients, 5341 were aged40 years and included in
the study; 775 patients who died during hospitalization orwho had
missing covariates were excluded. The baseline demographic and
clinical characteristics of the 4566 patients who met the inclusion
but not exclusion criteria are shown in Table 1. Themean ages of the
men and women were 70.3 (12.1) years and 72.7 (11.3) years,
respectively. The observed 30-day HF-specific readmission or death
rate after discharge was 9.8% (9.1% in men and 10.5% in women).
Patientswith a risk of 30-dayHF-specific readmission or deathwere
more likely to be older, have a lower bodyweight, and have a history
of HF admission, dilated cardiomyopathy, arrhythmia, cardiac
resynchronization therapy, an implantable cardiac defibrillator,
chronic obstructive pulmonary disease (COPD), chronic kidney
disease, or cancer. Values for LVEF and blood pressure were
significantly lower in patients who were readmitted or died.
Increased LOS and heavy drinkingwere also significantly associated
with30-dayHF-specific readmissionordeath. Theuseofb-blockers,
angiotensin-convertingenzyme inhibitors or angiotensin II receptor
blockers (ACEI/ARB), anddiureticsatdischargewas lower inpatients
with a risk of 30-day HF-specific readmission or death.
Three regression models used to predict the risk of 30-day HF-
specific readmissionordeathare showninTable2andeTable2 in the
SupplementaryAppendix. The complexmodel,whichusedmultiple
logistic regression, included the following: age, NYHA functional
class, clinicalhistory (hypertension, previousHFhospitalization, and
COPD), etiology of cardiomyopathy, systolic blood pressure, Na, BNP
or NT-proBNP, and prescription of b-blockers and ACEI/ARB at
discharge. We also presented a clinical model without blood
biomarkers, Na, BNP, and NT-proBNP in the complex model.
Using these coefficients of the complex model, the point risk
score for predicting the risk of 30-day readmission or death was
developed as shown in Table 3. The predicted risk for 30-day
readmission or death was simply calculated as the sum of the
scores assigned to each level of the individual risk factor.
Table 1
Baseline characteristics of study population (n=4566).
Variables 30-day HF-specific readmis-
sion or death
p-[2_TD$DIFF]value
No
(n=4120)
Yes
(n=446)
Age, years 70.312.1 72.711.3 <.0001
Women, % 48.0 51.8 0.1263
Current smoker, % 17.0 13.5 0.0584
Heavy drinker, % 6.8 3.8 0.0159
NYHA class (III or IV), % 84.8 90.8 0.0006
BMI, kg/m2 23.33.8 22.43.7 <0.0001
Clinical history, %
Hypertension 63.8 67.7 0.1046
Diabetes mellitus 40.7 44.2 0.1545
Heart failure 42.7 55.6 <0.0001
Heart failure admission 30.9 45.7 <0.0001
Ischemic heart disease 29.0 31.6 0.2454
DCM 7.0 15.3 <0.0001
Valvular disease 13.9 15.0 0.5289
Arrhythmia 33.4 39.0 0.0169
Atrial fibrillation 28.9 31.6 0.2181
COPD 10.9 17.1 <0.0001
CKD 13.8 21.4 <0.0001
Cerebrovascular disease 15.4 16.7 0.4358
Cancer 7.9 11.4 0.0093
ICD 1.3 2.7 0.0177
CRT 0.4 1.6 0.0008
Renal replacement, % 5.1 9.0 0.0003
HD 3.8 5.7 0.0388
CRRT 2.3 5.5 <0.0001
Dialysis other than above 0.2 0.8 0.0109
ICU, % 45.8 50.1 0.0679
SBP, mmHg 133.129.6 126.532.2 <0.0001
DBP, mmHg 79.418.2 75.418.4 <0.0001
Pulse, beat/min 92.326.0 90.323.3 0.0822
LVEF at discharge 40.615.7 37.116.1 <0.0001
Medication at discharge, %
ACEI/ARB 71.0 59.6 <0.0001
Beta-blocker 53.8 39.7 <0.0001
Diuretics 78.1 74.0 0.0459
Aldosterone antagonist 46.4 46.6 0.9189
Length of stay 13.015.3 15.920.4 0.0020
DCM, dilated cardiomyopathy; BMI, body mass index; ICD, implantable cardiac
defibrillator; CRT, cardiac resynchronization therapy; COPD, chronic obstructive
pulmonary disease; CKD, chronic kidney disease; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor antagonist; HD, hemodialysis;
HF, heart failure; CRRT, continuous renal replacement therapy; ICU, intensive
care unit; NYHA, New York Heart Association; LVEF, left ventricular ejection
fraction; ICU, intensive care unit.
Table 2
Multivariate predictors for 30-day HF-specific readmission or death.
Variables Clinical model Complex model
OR (95% CI) p-Value OR (95% CI) p-Value
Age (year) 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) 0.002
NYHA class III or IV 1.72 (1.22–2.41) 0.002 1.53 (1.08–2.16) 0.016
Clinical history
Hypertension 1.34 (1.07–1.68) 0.011 1.32 (1.05–1.67) 0.017
HF admission 1.50 (1.22–1.84) <0.001 1.43 (1.16–1.75) <0.001
COPD 1.51 (1.15–1.99) 0.003 1.62 (1.23–2.13) <0.001
Etiology of HF
Cardiomyopathy 1.48 (1.16–1.90) 0.002 1.54 (1.20–1.98) <0.001
SBP <110mmHg 2.06 (1.64–2.59) <0.001 2.00 (1.59–2.53) <0.001
LVEF <40% 1.40 (1.13–1.73) 0.002 1.24 (1.00–1.54) 0.053
b-Blockers at discharge 1.51 (1.23–1.86) <0.001 1.44 (1.17–1.78) <0.001
ACEI/ARB at discharge 1.54 (1.24–1.91) <0.001 1.46 (1.17–1.81) <0.001
Na <135mmol/L – – 1.91 (1.52–2.39) <0.001
BNP 700pg/mL or NTproBNP 8000pg/mL – – 1.92 (1.56–2.37) <0.001
HF, heart failure; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction;
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; Na, serum sodium level; BNP, brain natriuretic peptide; NT-proBNP, N-terminal
prohormone of brain natriuretic peptide; OR, odds ratio; CI, confidence interval.
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The AUCs of the basic, clinical, and complex prediction models
basedonthe logistic regressionanalyseswere0.647,0.679,and0.711,
respectively. The C-statistics were significantly increased after the
addition of the blood biomarkers (D = 0.032, p < 0.0001). Addition-
ally, the discrimination ability of the point risk score was almost
identical to that for the complex model (AUC = 0.710; vs. complex
model,p = 0.3998) (Fig.1andeTable3).Calibrationanalysisshoweda
good level of agreement between the observed risk and the risk
predicted by the complexmodel and point risk score (p = 0.8019 and
0.3826, respectively) butnot by thebasic and clinicalmodels (Fig. 2).
The user-category and category-free NRI were [3_TD$DIFF]0.17 (95% CI: 0.11–
0.24) and [4_TD$DIFF]0.42 (0.33–0.51), respectively, after the addition of two
blood biomarkers to the clinical model (eTable 4).
Discussion
Using data from a prospective, observational study of HF
patients, we propose a risk score to use in predicting 30-day HF-
specific readmission or death after hospital discharge. The risk
score comprises 12 variables, including age, NYHA functional class,
clinical history of hypertension, HF admission, COPD, etiology of
cardiomyopathy, SBP, LVEF, serum sodium level, and BNP or NT-
proBNP at discharge and the prescription of b-blockers and ACEI/
ARB at discharge. The risk score represents the first predictive
model developed specifically for use in a Korean population. This
study also shows that the point risk score achieves a moderate
level of discrimination and good overall calibration.
Frequent readmissions due to the worsening of HF leads to a
poor quality of life and presents a significant burden not only for
patients but also for their family and the public healthcare system.
The prevention of readmission after hospital discharge is therefore
a key contributor to reducing mortality and care costs and
improving the quality of life [26]. The identification and
stratification of patients according to their risk of early readmis-
sion or death at hospital discharge can support decision-making
regarding intensive medication and management. Additionally,
other interventions for patients and their caregivers, such as
education regarding the symptoms of HF and healthy lifestyles, can
be implemented to avoid early readmissions and improve
outcomes. The ability to predict likely readmission or death
within a relatively short period after discharge can be considered
particularly important because 61% of 30-day readmissions occur
within 15 days of discharge, and up to 50% of readmissions are
considered avoidable [27,28]. Accordingly, in the USA, outcomes,
such as the 30-day mortality or readmission rates, are reported by
the Centers forMedicare andMedicaid Services as ameasure of the
overall quality of care [29].
In recent years, there has been increased interest in the
assessment of the readmission risk, and several tools have been
developed to identify a range of risk factors, including clinical and
biochemical variables, institution-specific factors, and echocar-
diographic parameters [30–34]. These studies have found ethnic
and racial differences in the predictors and causes associated with
Table 3
Risk score for predicting 30-day heart failure-specific readmission or death.
Risk factor Level Score Total Risk (%) Total Risk (%)
Age (years) <50 0 0 1.0 21 20.0
50–59 1 1 1.2 22 22.5
60–69 2 2 1.4 23 25.3
70–79 3 3 1.6 24 28.3
80–89 4 4 1.8 25 31.5
90– 5 5 2.1 26 34.9
NYHA functional class III or IV 3 6 2.5 27 38.4
Clinical history 7 2.9 28 42.1
Hypertension Yes 2 8 3.3 29 45.8
Heart failure admission Yes 2 9 3.9 30 49.6
COPD Yes 3 10 4.5 31 53.4
Etiology 11 5.2 32 57.2
Cardiomyopathy Yes 3 12 6.0 33 60.9
SBP at discharge <110mmHg 5 13 6.9 34 64.4
LVEF <40% 1 14 7.9 35 67.8
b-Blockers at discharge No 2 15 9.1 36 71.1
ACEI/ARB at discharge No 2 16 10.4
Biochemical test 17 12.0 Total score
Na <135mmHg 4 18 13.6
BNP or NT-proBNP 700 or 8000pg/mL 4 19 15.5 [TD$INLINE]
Total score 0–36 20 17.7
NYHA, NewYork Heart Association; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction; ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; Na, serum sodium level; BNP, brain natriuretic peptide; NT-proBNP, N-terminal prohormone of
brain natriuretic peptide.
[(Fig._1)TD$FIG]
Fig. 1. Comparison of the receiver operating characteristic (ROC) curves among
three models and the point risk scores for predicting death or readmission risk
within 30 days after discharge. The areas under the curve (AUCs) of the three
models and point risk scoreswere 0.647 (95% CI, 0.620–0.674), 0.679 (0.653–0.705),
0.711 (0.0.686–0.737), and 0.710 (0.685–0.735), respectively.
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the readmission of patients with HF [35,36]. Among them, the
Readmission Risk Score developed by the Yale New Haven Health
Services Corporation/Center for Outcomes Research and Evalua-
tion (Yale/CORE) is the most well-known and widely implemented
risk predictionmodel for the standardized 30-day readmission risk
for patients with HF [30]. However, a recent validation study of
tertiary hospital patients in the USA showed the Yale/CORE score to
have only modest predictive ability [37]. The Yale/CORE score was
developed from the Medicare claims database, which comprises a
largely white population (only 16.3% of which have a non-white
background), most of whom are aged65 years; this indicates that
the score may not be applicable to patients aged <65 years and
those who are non-white and from different ethnic populations. A
recent study demonstrated that left ventricular filling pressure (E/
e0) and right atrial pressure are independently associated with 30-
day HF-specific hospital readmission. Additionally, these factors
added incremental prognostic value to the Yale/CORE score [33]. In
Southeastern Asia, a simple 30-day HF readmission risk score has
also been developed from an urban multi-ethnic Asian HF cohort
aged 65 years [38].
There are several distinct differences between the KorAHF and
previous studies with regard to patients’ clinical characteristics (at
admission and in the disease prognosis after discharge)
[21,22]. The initial blood pressure of the KorAHF population at
admission was not only considerably lower than that in other HF
studies but low SBP also had a significant impact on the 30-dayHF-
specific readmission or death rate. Severe symptoms, indicated by
a NYHA functional class of III–IV at admission, were also a
significant predictor of increased risk. Among serum biomarkers,
which are commonly measured in normal clinical settings, a low
sodium level and BNP or NT-proBNP showed a statistically
significant association with the 30-day HF-specific readmission
or death rate. In numerous previous studies, BNP and NT-proBNP
were shown to be the relevant predictors of readmission or death
[39–42]. The present study suggested that the optimal cut-off
points for Na, BNP, and NT-proBNP for prediction of the risk of 30-
day HF-specific readmission or death after discharge were
135 mmol/L, 700 pg/mL, and 8000 pg/mL, respectively, which
were determined by proper optimality criteria.
Although the effect of LVEF on HF readmissionwas inconsistent
and controversial [35], the present study suggests that patients
with an LVEF<40%weremore likely to undergo 30-dayHF-specific
readmission or death. We also found that evidence-based drug
therapies for HF patients, includingb-blockers and ACEI/ARB, were
beneficial in decreasing the risk of readmission or death. The
effectiveness of b-blockers and ACEI/ARB in reducing the risk of
death or rehospitalization in HF patients was reported in
randomized controlled clinical trials and observational studies
[43–45]. In the Organized Program to Initiate Lifesaving Treatment
in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) study,
prescription ofb-blockers at dischargewas associatedwith a lower
mortality rate, and ACEI or ARBs were associated with decreased
levels of readmission or death [46].
The key strength of the present study is its use of clinical
information derived from a prospective multicenter cohort study
of 20 tertiary hospitals to develop a risk score. Additionally, this
risk score can be applied to a relatively wide range of age groups
because it was developedwith a younger population than previous
models from other countries. Nonetheless, the limitations of the
study include the fact that our risk score has not been validated in
an external dataset, a step that will be required to evaluate the
performance of our model. Further evaluationwill also be required
to determine whether our score can be applied to a wider general
population and different ethnic groups.
Conclusions
Inconclusion, thisstudypresentsasimpleapproachtoestimating
the risk of 30-day HF-specific readmission or death in HF patients
following hospital discharge. The proposed risk score has the
potential to reduce relatively short-termHF-specific readmission or
death by identifying high-risk patients and therefore directing
intensive medical monitoring and suitable rehabilitation toward
those patients most likely to benefit from these interventions. An
additional validation study will be required to determine whether
the risk score is applicable to other populations.
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